Skip to content

Tango Therapeutics, Inc.

TNGX

CIK 0001819133

← back to feed
Revenue (TTM)
$62.38M
+48.3% YoY Q1 May 2026
Net Income (TTM)
−$108.36M
+22.0% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.90
+26.9% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-189.5%
Q1 May 2026
Net Margin
-173.7%
Q1 May 2026
Free Cash Flow (TTM)
−$159.69M
Q1 May 2026
Cash
$157.83M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
144.65M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings